As part of the continuing professional education slide resource programme, PCSK9 Forum announces the next in a series of complementary slide decks.

Why does immunotherapy offer a new approach to improve LDL cholesterol goal attainment?

Therapeutic approaches to managing LDL cholesterol focus on small molecule drugs, such as statins. Although effective, these also pose a number of challenges for clinicians, including their specificity, dosing interval, variability in responsiveness and potential for drug-drug interactions. Additionally, due to their small size, there is also the possibility that these agents may cross the blood-brain barrier.

The discovery of PCSK9 as a key player in the regulation of circulating LDL cholesterol levels paved the way for a new therapeutic approach: monoclonal antibody therapy targeting PCSK9.

The latest complementary slide resource from PCSK9 Forum provides a background to immunotherapy for clinicians involved in the management of patients with hypercholesterolaemia, highlighting the advantages of this novel therapeutic approach.

Bookmark PCSK9 Forum to return for regular updates to this innovative expert-led educational slide resource programme.